Zacks Investment Research downgraded shares of ACCELRYS INC (ACCL) from OUTPERFORM to NEUTRAL on December 06, 2012, with a target price of $10.10.
Accelrys Inc. provides scientific innovation and technology leadership in delivering software and service solutions that span the continuum of discovery and development research. A unique combination of expertise in life and materials science, informatics, and scientific operating platform technology lets Accelrys serve a diverse range of clients, including some of the world's leading pharmaceutical, biotechnology, chemical and nanotechnology research organizations. Accelrys is headquartered in San Diego, California.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on ACCELRYS INC (ACCL),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment